资讯
TipRanks on MSN
Incyte announces additional FDA approval of Opzelura
Incyte (INCY) “announced that the FDA has approved Opzelura cream 1.5%, a topical Janus kinase inhibitor, for the short-term and non-continuous ...
The Knights hope to wrap up their nonconference slate undefeated before opening Big 12 play next week against Kansas State.
一些您可能无法访问的结果已被隐去。
显示无法访问的结果